https://www.targetedonc.com/view/safety-of-tucatinib-triplet-for-her2-breast-cancer-sealed-in-real-world-analysis
0
0
12/8/22 at 7:21pm
Organization
Targetedonc.com
Author
Lisa Astor
42 words
0
Comments
Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.
You are the first to view
Create an account
or login to join the discussion